Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds up in Study

Dow Jones

Oct 06

Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21.

Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2673869150"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2673869150\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2673869150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-06 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673869150","market":"us","top_or_hot":-1,"title":"Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds up in Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21. \n</p>\n<p>\n     Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028. \n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Under the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds up in Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnder the Radar: Vaxcyte Stock Jumps After Pneumonia Vaccine Holds up in Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-10-06 00:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21. \n</p>\n<p>\n     Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028. \n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCVX","symbol_name":"Vaxcyte, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2673869150","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2673869150","pubTimestamp":1791218880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21.Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCVX":"Vaxcyte, Inc.","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4139":"生物科技"},"translate_title":"雷达下：肺炎疫苗在研究中停滞不前后，Vaxcyte 股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1.5},"content_text":"Vaxcyte shares jumped more than 25% Monday after the company said its experimental pneumonia vaccine held up against the two shots now on the market in a large final-stage trial. The vaccine, called VAX-31, targets 31 strains of the bacteria that cause pneumonia, meningitis and bloodstream infections. It is set to compete with Pfizer's Prevnar 20, which covers 20 strains, and Merck's Capvaxive, which covers 21. \n\n\n     Vaxcyte said VAX-31 showed immune responses comparable to the rival shots on all 28 strains it shares with them. The company also said VAX-31 produced stronger immune responses than the existing shots on three strains only it covers. It fell short of the study's main target on two strains against Merck's shot. The company expects to report data from two more trials in the first half of 2027, and said it plans to seek FDA approval of the shot in the first half of 2028.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}